NASDAQ: FIXX |
| Healthcare / Biotechnology / USA |
2.03 | -0.2200 | -9.78% | Vol 4.37M | 1Y Perf -69.22% |
Jun 24th, 2022 16:00 DELAYED |
BID | 1.90 | ASK | 2.37 | ||
Open | 2.25 | Previous Close | 2.25 | ||
Pre-Market | - | After-Market | 2.08 | ||
- - | 0.05 2.46% |
Target Price | 13.83 | Analyst Rating | Moderate Buy 2.00 | |
Potential % | 581.28 | Finscreener Ranking | ★★★★★ 59.99 | |
Insiders Trans % 3/6/12 mo. | -/-100/-100 | Value Ranking | ★★★★ 56.98 | |
Insiders Value % 3/6/12 mo. | -/-100/-100 | Growth Ranking | ★★★★+ 65.40 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 9.61 | Earnings Rating | Sell | |
Market Cap | 116.49M | Earnings Date | 11th Aug 2022 | |
Alpha | -0.03 | Standard Deviation | 0.17 | |
Beta | -0.21 |
Today's Price Range 2.022.39 | 52W Range 1.308.90 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Buy |
Performance | |||
---|---|---|---|
1 Week | 13.41% | ||
1 Month | 41.96% | ||
3 Months | -33.66% | ||
6 Months | -50.97% | ||
1 Year | -69.22% | ||
3 Years | -89.24% | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -47.50 | |||
ROE last 12 Months | -1.11 | |||
ROA (5Y Avg) | -24.07 | |||
ROA last 12 Months | -0.95 | |||
ROC (5Y Avg) | -45.94 | |||
ROC last 12 Months | -1.09 | |||
Return on invested Capital Q | 38.06 | |||
Return on invested Capital Y | -16.58 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-22.40 | ||||
0.39 | ||||
18.79 | ||||
57.40 | ||||
6.20 | ||||
-1.94 | ||||
0.39 | ||||
4.64 | ||||
-129 423 000.00 | ||||
Forward PE | -0.92 | |||
PEG | -1.17 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
12.30 | ||||
12.60 | ||||
0.08 | ||||
0.09 | ||||
- | ||||
Leverage Ratio | 1.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
-2 422.40 | ||||
-2 301.30 | ||||
- | ||||
-47.29 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
5.47M | ||||
0.10 | ||||
91.32 | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | -0.25 | -0.20 | 20.00 |
Q04 2021 | -0.58 | -0.59 | -1.72 |
Q03 2021 | -0.60 | -0.54 | 10.00 |
Q02 2021 | -0.58 | -0.54 | 6.90 |
Q01 2021 | -0.65 | -0.02 | 96.92 |
Q04 2020 | -0.65 | -0.62 | 4.62 |
Q03 2020 | -0.81 | -0.62 | 23.46 |
Q02 2020 | -0.81 | -0.78 | 3.70 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | -0.57 | -7.55 | Negative |
9/2022 QR | -0.57 | -1.79 | Negative |
12/2022 FY | -1.86 | 3.13 | Positive |
12/2023 FY | -1.93 | 11.06 | Positive |
Next Report Date | 11th Aug 2022 |
Estimated EPS Next Report | -0.57 |
Estimates Count | 5 |
EPS Growth Next 5 Years % | 19.10 |
Volume Overview | |
---|---|
Volume | 4.37M |
Shares Outstanding | 57.39K |
Shares Float | 46.83M |
Trades Count | 6.06K |
Dollar Volume | 8.95M |
Avg. Volume | 453.84K |
Avg. Weekly Volume | 484.42K |
Avg. Monthly Volume | 443.88K |
Avg. Quarterly Volume | 433.22K |
Homology Medicines Inc. (NASDAQ: FIXX) stock closed at 2.03 per share at the end of the most recent trading day (a -9.78% change compared to the prior day closing price) with a volume of 4.37M shares and market capitalization of 116.49M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 206 people. Homology Medicines Inc. CEO is Arthur O. Tzianabos.
The one-year performance of Homology Medicines Inc. stock is -69.22%, while year-to-date (YTD) performance is -44.23%. FIXX stock has a five-year performance of %. Its 52-week range is between 1.3 and 8.9, which gives FIXX stock a 52-week price range ratio of 9.61%
Homology Medicines Inc. currently has a PE ratio of -22.40, a price-to-book (PB) ratio of 0.39, a price-to-sale (PS) ratio of 18.79, a price to cashflow ratio of 57.40, a PEG ratio of 2.32, a ROA of -0.95%, a ROC of -1.09% and a ROE of -1.11%. The company’s profit margin is -47.29%, its EBITDA margin is -2 301.30%, and its revenue ttm is $5.47 Million , which makes it $0.10 revenue per share.
Of the last four earnings reports from Homology Medicines Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.57 for the next earnings report. Homology Medicines Inc.’s next earnings report date is 11th Aug 2022.
The consensus rating of Wall Street analysts for Homology Medicines Inc. is Moderate Buy (2), with a target price of $13.83, which is +581.28% compared to the current price. The earnings rating for Homology Medicines Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Homology Medicines Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Homology Medicines Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 19.27, ATR14 : 0.22, CCI20 : 84.89, Chaikin Money Flow : -0.30, MACD : 0.07, Money Flow Index : 37.37, ROC : -8.56, RSI : 54.55, STOCH (14,3) : 48.65, STOCH RSI : 0.44, UO : 51.93, Williams %R : -51.35), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Homology Medicines Inc. in the last 12-months were: Albert Seymour (Option Excercise at a value of $0), Albert Seymour (Sold 1 661 shares of value $6 279 ), Arthur O. Tzianabos (Option Excercise at a value of $0), Arthur O. Tzianabos (Sold 5 354 shares of value $20 239 ), Gabriel Cohn (Option Excercise at a value of $0), Gabriel Cohn (Sold 1 661 shares of value $6 279 ), Timothy P. Kelly (Option Excercise at a value of $0), Timothy P. Kelly (Sold 2 974 shares of value $11 877 ), W. Bradford Smith (Option Excercise at a value of $0), W. Bradford Smith (Sold 2 182 shares of value $8 248 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Homology Medicines Inc is an US based is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
CEO: Arthur O. Tzianabos
Telephone: +1 781 301-7277
Address: One Patriots Park, Bedford 01730, MA, US
Number of employees: 206
Tue, 17 May 2022 12:43 GMT Homology Medicines (FIXX) Gets a Hold Rating from Credit Suisse
- TipRanks. All rights reserved.Mon, 28 Feb 2022 11:25 GMT Analysts Offer Insights on Healthcare Companies: Homology Medicines (FIXX), Y-Mabs Therapeutics (YMAB) and Cardiff Oncology (CRDF)
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.